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318Objective: The purpose of this study was to test the hypothesis that a liberal blood glucose strategy (121–180
mg/dL) is not inferior to a strict blood glucose strategy (90–120 mg/dL) for outcomes in patients after first-time
isolated coronary artery bypass grafting and is superior for glucose control and target blood glucose management.
Methods: A total of 189 patients undergoing coronary artery bypass grafting were investigated in this prospec-
tive randomized study to compare 2 glucose control strategies on patient perioperative outcomes. Three methods
of analyses (intention to treat, completer, and per protocol) were conducted. Observed power was robust (>80%)
for significant results.
Results: The groups were similar on preoperative hemoglobin A1c and number of diabetic patients. The liberal
group was found to be noninferior to the strict group for perioperative complications and superior on glucose
control and target range management. The liberal group had significantly fewer patients with hypoglycemic
events (<60 mg/dL; P<.001), but severe hypoglycemic events (<40 mg/dL) were rare and no group differences
were found (P ¼ .23). These results were found with all 3 methods of analysis except for blood glucose vari-
ability, maximum blood glucose, and perioperative atrial fibrillation.
Conclusions: This study demonstrated that maintenance of blood glucose in a liberal range after coronary artery
bypass grafting led to similar outcomes compared with a strict target range and was superior in glucose control
and target range management. On the basis of the results of this study, a target blood glucose range of 121 to 180
mg/dL is recommended for patients after coronary artery bypass grafting as advocated by the Society of
Thoracic Surgeons. (J Thorac Cardiovasc Surg 2012;143:318-25)Earn CME credits at
http://cme.ctsnetjournals.org
In recent years, data have shown that uncontrolled hyper-
glycemia is associated with poor clinical outcomes after
surgical interventions.1-7 Likewise, control of glucose can
improve outcomes in critically ill patients. Since the
landmark study by Van den Berghe and colleagues2 in
2001, there have been guidelines for strict glycemic control
in the intensive care unit (ICU). Over the past several years,
the debate has been which patient population (surgical or
medical) will benefit most from strict glycemic control
and how strict a protocol is required.1-7e Inova Heart and Vascular Institute, Falls Church, Va.
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The Journal of Thoracic and Cardiovascular SurgHyperglycemia is commonly encountered after cardiac
surgery, whether a patient has a history of diabetes or
not.1 Hyperglycemia has been associated with increased
perioperative morbidity and mortality; several studies
have demonstrated that glycemic control using insulin
protocols improves operative mortality, lowers operative
morbidity, and improves long-term survival.2-4
Although the consensus is that hyperglycemia should be
managed after surgery, the optimal target serum glucose
level that minimizes both perioperative complications and
hypoglycemic events has yet to be established. In 2004,
Lazar and colleagues6 demonstrated that maintaining the se-
rum glucose between 120 and 180mg/dL in diabetic patients
undergoing cardiac surgery is safer and that a stricter regi-
men did not contribute to improved outcome. However, their
study dealt only with diabetic patients, who comprise less
than 50% of the operated population in the majority of cen-
ters. The Society of Thoracic Surgeons (STS) recommends
that insulin infusions be titrated to maintain serum glucose
at less than 180 mg/dL for the duration of the perioperative
ICU stay.2,4 The recently completed Normoglycemia
in Intensive Care Evaluation-Survival Using Glucose
Algorithm Regulation (NICE-SUGAR) trial found that in-
tensive glucose control (81–108 mg/dL) actually increased
90-day mortality compared with a more liberal glucoseery c February 2012
Abbreviations and Acronyms
BG ¼ blood glucose
CABG ¼ coronary artery bypass grafting
ICU ¼ intensive care unit
NICE-SUGAR ¼ Normoglycemia in Intensive
Care Evaluation-Survival
Using Glucose Algorithm
Regulation
STS ¼ Society of Thoracic Surgeons
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study was not focused solely on patents undergoing cardiac
surgery and was mainly comprised of nonoperative patients,
often with sepsis and multiorgan dysfunction.
Lazar and colleagues8 recently completed a prospective,
randomized trial in diabetic patients undergoing coronary ar-
tery bypass grafting (CABG) to determinewhether tight gly-
cemic control (90–120mg/dL) would result in more optimal
clinical outcomes than a more moderate glycemic control
(120–180mg/dL). They found that tight glycemic control in-
creased the incidence of hypoglycemic events, but did not re-
sult in any significant improvement in clinical outcomes that
was achieved with the more moderate control; however, this
study also dealt only with diabetic patients. For the past sev-
eral years, our patient management has dictated strict glyce-
mic control with blood glucose (BG) levelsmaintained in the
range of 90 to less than 120mg/dL for all patients undergoing
cardiac surgery. Our study aimed to compare the current
practice of strict control with a liberal strategy: BG main-
tained at less than 180 mg/dL (121–180 mg/dL).MATERIALS AND METHODS
A randomized controlled study was performed to test the hypothesis that
a liberal strategy of serum glucose control (BG 121–180 mg/dL) is not in-
ferior to a strict strategy (BG 90–120 mg/dL) in patients after first-time iso-
lated CABG for complications and outcomes and is superior for glucose
control and target BG management.
This study was a prospective, randomized controlled single-center clin-
ical trial that examined adult patients undergoing first-time isolated CABG
in whom hyperglycemia developed, thus requiring insulin therapy for treat-
ment. All patients, regardless of a history of diabetes, were eligible for in-
clusion in this trial if they had 3 or more blood glucose readings of more
than 150 mg/dL or 1 BG reading more than 200 mg/dL (considered our
standard of care). The study was approved by the Human Research Protec-
tion Program at Inova Heart and Vascular Institute (institutional review
board number 09.111), and informed consent was obtained from all pa-
tients. This study was also registered on ClinicalTrials.gov.INCLUSION CRITERIA
1. All diabetic patients who underwent first-time, isolated,
nonemergency CABG.
2. Nondiabetic patients who underwent first-time, isolated,
nonemergency CABG who were found to have had 3The Journal of Thoracic and Caconsecutive BG readings greater than 150 mg/dL or
any 1 BG reading greater than 200 mg/dL periopera-
tively, which is aligned with the current STS guidelines.
3. Patients who were started on an insulin infusion while in
the operating room.
EXCLUSION CRITERIA
1. Patients who underwent open surgery other than isolated
CABG.
2. Patients who were found not to require an insulin infu-
sion post-CABG.
3. Patients who underwent a concomitant procedure in ad-
dition to CABG (eg, CABGþvalve repair).STUDY TREATMENTAND INTERVENTION
Once enrolled, patients underwent a series of preopera-
tive blood tests, anthropomorphic measurements, and as-
sessment scales and inventories as noted in Figure 1.
Questionnaires assessing depression (Patient Health Ques-
tionnaire 9), health-related quality of life (Short Form-
12), diet, and physical activity (Duke Activity Score)
were filled out by patients preoperatively, although these re-
sults will not be included in the present analyses.
Intraoperative glucose measures and interventions were
under the purview of the anesthesiologist, whose goal was
to maintain a BG level between 100 and 180 mg/dL. Main-
tenance of BG levels according to their randomized arm
was started in the ICU using the programmed Glu-
commander (Gluco Tec, Greenville, SC) to adjust the BG
level to patients’ assigned range. The nursing staff was
not blinded to treatment group allocation. Hourly BG mon-
itoring was performed with blood obtained from a patient’s
arterial line and analyzed by point of care testing through
Glucose Accu-Chek Advantage with the AccuData GTS/
GTS manufactured by Roche (Basel, Switzerland). BG
levels less than 40 mg/dL or greater than 500 mg/dL were
sent to the laboratory for further analysis; however, treat-
ment was initiated for low BG if indicated. Patients were
maintained on the electronic-based protocol of intravenous
insulin for a minimum of 72 hours perioperatively.
GLUCOMMANDER
The Glucommander is a Food and Drug Administration–
approved computer software system for controlling BG de-
signed to assist clinicians in obtaining and then maintaining
glucose control by calculating the insulin dose required to
achieve the target range in response to measurement of BG
at the patient’s bedside, but does not administer the insulin.
It is the current method of glycemic control for patients
post-CABG at our institution. We previously validated9 in-
creased efficiency and efficacy of Glucommander data.
The Glucommander uses the variables of patients’ height,
weight, HbA1C, and current and cumulative BG values tordiovascular Surgery c Volume 143, Number 2 319
FIGURE 1. Trial design. CVICU, Cardiovascular intensive care unit;OR, odds ratio; CABG, coronary artery bypass grafting; PHQ9, Patient Health Ques-
tionnaire 9; CBC, complete blood count; BMP, basic metabolic panel; HgBA1C, hemoglobin A1C; LFT, liver function test; HDL, high-density lipoprotein;
LDL, low-density lipoprotein; Gtt, glucose tolerance test; Glu, glucose; MACE, major adverse cardiac event.
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lin or glucose to maintain individual patient BG levels in
a predetermined range. The bedside nurses were responsi-
ble for carrying out any indicated intervention to include in-
sulin infusion adjustment or glucose administration and
further BG monitoring.RANDOMIZATION
A block randomization process was used to randomly as-
sign patients into the 2 groups (strict or liberal) with blocks
of 10 patients. If the randomization scheme determined the
patient was to be in the liberal arm, then an order was writ-
ten in the chart to change the Glucommander parameters for
a target glucose range of 121 to 180 mg/dL. If the random-
ization scheme determined the patient was to be in the strict
arm, then the patient continued on the standard CABG post-
operative orders, mandating strict glycemic control with
a target glucose range of 90 to 120 mg/dL.
END POINTS AND OUTCOMES MEASUREMENT
The primary end points were 2-fold: superiority hypoth-
esized for glucose control and target management and non-320 The Journal of Thoracic and Cardiovascular Surginferiority hypothesized for complications and outcomes.
Superiority end points included time to target glucose
range, amount of insulin given, number of readings in target
range, and number of patients with hypoglycemic events
(BG< 60 mg/dL and BG< 40 mg/dL). Noninferiority
end points included perioperative renal failure, deep sternal
wound infection, pneumonia, length of stay, atrial fibrilla-
tion, and operative mortality (death within 30 days).
DATA ANALYSIS
The data for this article were managed using SAS/STAT
software, version 9.1 of the SAS System (SAS Institute Inc,
Cary, NC). Statistical analysis was performed with SPSS
version 17.0 (SPSS Inc, Chicago, Ill). The groups were
compared on categorical variables with the chi-square test
or 2-sided Fisher exact test, as appropriate. Student t test
compared continuous variables. All outcomes initially
were evaluated by intention-to-treat analyses. However, be-
cause of crossover between the 2 treatment arms, completer
analyses (actual treatment received) and per protocol anal-
yses (only those that received the treatment they were ran-
domized to) were examined as a secondary step. A prioriery c February 2012
FIGURE 2. Flow of participants. CABG,Coronary artery bypass grafting.
TABLE 1. Patient characteristics (intention-to-treat; no significant
group differences)
Strict
n ¼ 91
Liberal
n ¼ 98
P
value
Age, y 62.5  10.2 62.8  9.5 .87
Female 10 (11) 20 (20) .11
Diabetes 37 (41) 44 (45) .56
Hemoglobin A1c 6.64  1.52 6.48  1.28 .44
Hypertension 75 (82) 84 (86) .56
Congestive heart failure 12 (13) 9 (9) .49
Ejection fraction 57  8 56  9 .40
Aspirin 84 (92) 92 (94) .78
Beta-blockers 77 (85) 91 (93) .10
ACE/ARB inhibitors 46 (51) 46 (47) .62
Lipid-lowering medications 84 (92) 92 (94) .78
STS risk percentage 1.4  2.2 1.1  2.1 .36
euroSCORE (additive) 3.97  2.98 3.67  2.65 .47
ACE, Angiotensin-converting enzyme; ARB, angiotensin receptor blocker; euro-
SCORE, European System for Cardiac Operative Risk Evaluation.
TABLE 2. Results of the noninferiority analyses for clinical outcomes
(intention-to-treat)
Strict
n ¼ 91
Liberal
n ¼ 98
Treatment
difference 95% CI
Renal failure 2.2% 0 0.022 0.05 to 0.008
Atrial fibrillation 8.0% 10.2% 0.022 0.06 to 0.10
Pneumonia 2.2% 0 0.022 0.05 to 0.008
Deep sternal wound
infection
1.1% 0 0.011 0.03 to 0.01
Prolonged ventilation
(>24 h)
3.3% 0 0.033 0.07 to 0.004
MACE 2.2% 2.0% 0.002 0.04 to 0.04
LOS>10 d 3.3% 2.0% 0.013 0.06 to 0.03
Operative mortality 1.1% 1.0% 0.001 0.03 to 0.03
CI, Confidence interval; MACE, major adverse cardiac event; LOS, length of stay.
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dium effect sizes with alpha set at 0.05 and power set at
80%. Observed power was found to be robust (>80%)
for all analyses except those where no significance was
found, given the smaller observed effect sizes for those
comparisons.
We conducted noninferiority analyses to examine the
effect of target range on clinical outcomes and complica-
tions. Noninferiority was declared if the effect difference
and entire 95% confidence interval for the event rate in
the liberal group did not exceed a relative margin of 10%
(0.10 to 0.10) from the event rate in the strict group.
RESULTS
Patient Characteristics
This study randomized 189 patients to the strict or liberal
target range (Figure 2). All results are reported using the
intention-to-treat model, unless otherwise noted. The
mean age of the patients was 62.7  9.8 years, and 16%
of the sample was female. There were no differences be-
tween the groups on baseline characteristics, including all
markers from the preoperative blood panel and preoperative
cardioprotective medications (Table 1). Diabetic patients
were evenly distributed between the groups.
Superiority of Glucose Control and Target Range
Management
Patients in the liberal group were found to reach their tar-
get range in less than half the time as the strict group (83.5
 134.6 vs 173.3 195.8 minutes; t¼ 3.65, P<.001). The
liberal group had more readings within the target range
compared with the strict group (27.0  5.5 vs 23.6  5.3;
t¼4.31, P<.001), significantly fewer readings above tar-
get range (7.7  6.3 vs 13.1  6.1; t ¼ 6.05, P<.001), and
reduced variability (standard deviation) across the 72 hours
(26.7  9.5 vs 29.8  10.8; t ¼ 2.08, P ¼ .04). There was
no difference between the liberal and strict groups on max-
imum BG (218.3  46.8 vs 213.3  48.2; t ¼ 0.72,
P ¼ .47). The minimum BG level was higher in the liberalThe Journal of Thoracic and Cagroup (84.4  17.8 vs 66.6  13.9 mg/dL; t ¼ 7.64,
P<.001). The liberal group had fewer patients with at least
1 hypoglycemic event (BG< 60 mg/dL) than the strict
group (11 [11%] vs 30 [33%], P<.001). However, there
was not a difference in the number of patients who experi-
enced severe hypoglycemia (BG<40 mg/dL) between the
groups (0 vs 2 [2.2%], P¼ .23), but the occurrence of these
events was rare. The number of readings did not differ
between the groups (t ¼ 1.01, P ¼ .31), a factor controlled
by the Glucommander system. Last, the liberal group
required fewer total units of insulin compared with the
strict group (166.0  156.7 vs 252.3  193.4; t ¼ 3.36,
P<.001).
Noninferiority of Perioperative Complications and
Outcomes
Event rates were small for perioperative complications
and clinical outcomes. There were no incidences of perio-
perative myocardial infarction, permanent stroke, or legrdiovascular Surgery c Volume 143, Number 2 321
FIGURE 3. Treatment difference and 95% confidence interval for noninferiority of perioperative complications and outcomes: intention-to-treat analyses
(A), completer analyses (B), and per protocol analyses (C). DSW, Deep sternal wound infection;MACE,major adverse cardiac events; LOS, length of stay.
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be noninferior to the strict group on all outcome variables
(Table 2 and Figure 3, A).
Completer Analyses (as Treated)
As shown in Figure 2, 11 patients randomized to the strict
group received the liberal target range and 27 patients ran-
domized to the liberal group received the strict range due to
clinical practice factors beyond the control of the study, in-
cluding caregiver personnel changing or failing to change
the preset target range on the Glucommander device. To en-
sure bias was not introduced in these results, completer
analyses were conducted to examine the target range groups
based on what the patient actually received (liberal ¼ 82,
strict ¼ 107). These analyses revealed that all superiority
and noninferiority analysis results were similar to that of
the intention-to-treat analyses. The only exceptions were
found for maximum BG, BG variability, and perioperative
atrial fibrillation. In the completer analyses, the liberal
group was not different on variability (27.4  11.2 vs
28.8  9.5; t ¼ 0.93, P ¼ .35) and had significantly higher
maximum BG compared with the strict group (229.0 49.6
vs 205.9  43.3; t ¼3.41, P<.001), whereas this effect
was attenuated in the intention-to-treat analysis and no sig-
nificant differencewas found (t¼0.72, P¼ .47). Although
the treatment difference for perioperative atrial fibrillation
(0.035) was within the noninferiority margin, the entire
95% confidence interval was not (0.05 to 0.12; Figure 3,
B) and therefore did not meet our criteria for noninferiority.
Per Protocol Analyses
A third method of analysis was conducted to examine
those patients whose actual treatment arm matched their
randomized group (liberal ¼ 71, strict ¼ 80). Again, supe-
riority and noninferiority analysis results were similar to
that of the intention-to-treat analyses with the exceptions
of maximum BG, BG variability, and perioperative atrial fi-
brillation. In the per protocol analyses, the liberal group was
not different on variability (26.4  9.8 vs 29.3  9.7;
t ¼ 1.78, P ¼ .08) and had significantly higher maximum
BG compared with the strict group (225.9  47.7 vs322 The Journal of Thoracic and Cardiovascular Surg208.5 44.9; t¼2.32, P¼ .02). The treatment difference
for perioperative atrial fibrillation (0.036) was within the
noninferiority margin, but not the 95% confidence interval
(0.05 to 0.12; Figure 3, C).
DISCUSSION
Regardless of the method of analysis, the liberal group
was significantly superior to the strict group on the out-
comes of time to target BG range, the number of patients
with hypoglycemic events (BG<60 mg/dL), and the num-
ber of readings that BG levels were within their respective
target ranges. The more liberal group (BG target range of
121–180 mg/dL) had a quicker time to target BG range after
admission to the cardiovascular ICU, was maintained
within its specified target range, had fewer patients with hy-
poglycemic events, and was not inferior on perioperative
complications. The liberal group was also noninferior to
the strict group in the perioperative outcomes of prolonged
ventilation, deep sternal wound infection, pneumonia, peri-
operative renal failure, and operative mortality. On the basis
of these results, it seems reasonable to set the target BG
range to between 121 and 180 mg/dL for this group of pa-
tients undergoing first-time isolated CABG.
These findings are consistent with the recommendations
of Lazar and colleagues5,6 and the STS guidelines that
were developed from a series of clinical trials to include
the work by Lazar and colleagues. Currently, the STS has
recommended that patients undergoing cardiac surgery
have their BG levels maintained at less than 180 mg/dL
while in the ICU (level A) and that the most efficient way
to achieve glucose control is with insulin infusions (level
A). They further suggest that postprandial BG levels on
the stepdown unit should also be maintained at less than
180 mg/dL (level B) using oral agents if previously
prescribed or subcutaneous basal and bolus insulin
therapy, such as glargine and lispro.5 All our study patients
were maintained on insulin infusions for the first 72 hours
if they had 3 sequential BG levels greater than 150 mg/dL
immediately perioperatively. On the morning of the third
day, patients were subsequently weaned from the insulin
drip and started on prior prescribed medication or insulinery c February 2012
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in the liberal group (BG 121–180mg/dL) fared better in glu-
cose control requiring less insulin, were in target more often,
and had a smoother transition off their insulin infusions than
the patients in the strict control group (BG 90–120 mg/dL).
Our findings are also in line with the just released Amer-
ican College of Physicians guidelines for intensive insulin
therapy in hospitalized patients. Although the guidelines
are not specific to the cardiac surgical patient, they do ad-
dress patients in the ICU (surgical and mobile ICU). The
task force recommends against using intensive-insulin ther-
apy, but rather using conventional glucose control mecha-
nisms to achieve BG control. However, they also state
that if intensive insulin therapy is used then the BG target
level should be kept between 140 and 200 mg/dL.10 The av-
erage BG level was 133  17 (range 98–183) in the liberal
group during the first 24 hours after surgery, 134  20
(range 95–181) for the second 24 hours, and 124  18
(range 90–166) for the third 24 hours, which is closely in
line with these recommendations.
The NICE-SUGAR trial was recently completed, and the
findings indicate that in this large, international randomized
trial intensive glucose control increased mortality among
adults in the ICU. The investigators concluded that a BG
target of less than 180 mg/dL was an appropriate level to
achieve.7
Our study design was also similar to the NICE-SUGAR
trial. In the NICE-SUGAR trial, 6104 patients were ran-
domized to an intensive glucose control arm (target BG of
81–108 mg/dL) or a conventional control arm (target BG
of< 180 mg/dL), and patients were enrolled from both
medical and surgical ICUs. In our study, we randomized pa-
tients to an intensive glucose control arm, with a target
range of 91 to 120 mg/dL, or to a liberal control arm,
with a target BG range of 121 to 180 mg/dL. In the
NICE-SUGAR trial, 6.8% of the patients in the intensive
control group experienced severe hypoglycemia (BG level
 40 mg/dL), which was significantly different than the
0.5% of the patients in the conventional treatment group
(P< .001).7 Our findings were similar in that patients in
the strict glucose control group did have significantly
(P < .001) more hypoglycemic episodes (<60 mg/dL;
33%) than the liberal group (11%), although the groups
were not significantly different in the number of patients
with severe hypoglycemia (<40 mg/dL; 2.2% vs 0%,
P¼ .23). It is possible that there was not a significant differ-
ence between the 2 groups in severe hypoglycemia because
of the use of the computer software program (Glu-
commander) for insulin management. The Glucommander
instructed the bedside nurse on exactly what to administer
according to the glucose level, so there was no delay in
treatment. We also noted that most of the hypoglycemic
events occurred late on the second day and into the third
day around the time the patient had started to eat a regularThe Journal of Thoracic and Cadiet causing the blood glucose to spike. The spike in the
blood glucose caused the computer algorithm to adapt,
but did not allow for an expected decrease in the postpran-
dial BG level. This issue is currently being addressed as
Glucommander updates its algorithm to allow for patients
eating a regular diet.9
A rather striking finding of our study is the amount of
time we found that patients actually were within their as-
signed target range, that is, the variability of BG values.
We found the strict group spent significantly less time
within their target range than the more liberal group despite
hourly blood draws and insulin adjustments. Using the
intention-to-treat analysis, there was also a significant dif-
ference between the groups on standard deviation across
the 72-hour time period. Several recent studies have actu-
ally questioned whether it is the variability of the BG values
rather than the mean that influenced outcomes.11-18 Egi and
Bellomo11 postulate that the difference in variability of BG
control may be the reason why intensive insulin therapy has
varied from beneficial to harmful, especially when compar-
ing the Leuven19 (higher variability in the control arm) trial
with the NICE-SUGAR7 (equivalent in both arms) trial and
their respective outcomes and recommendations.
Another strength of this study was that all 3 methods of
analyses maintained robust power. The a priori sample
size of this study (N¼ 200) was determined to be sufficient
using a medium effect size, an alpha level of 0.05, and 80%
power.20 Observed power was found to be robust for signif-
icant results, but not robust for nonsignificant results as ex-
pected, given the much smaller observed effect sizes for
those comparisons. The strong power of this study allowed
us to detect significant results on almost all of the superior-
ity analyses and noninferiority on the clinical outcomes.
However, the fact that we were unable to find non-
inferiority on atrial fibrillation using the completer and
per protocol analyses may be because this particular perio-
perative outcome has a small event rate at our facility. At
Inova Heart and Vascular Institute, we aggressively pretreat
all our patients undergoing cardiac surgery with amiodar-
one such that our institutional event rate (10%–13%) is
well below the national average as reported by the STS
(23%–24%) and was only 9% in this study.21 Therefore,
more patients are needed to investigate this particular out-
come before any conclusion may be drawn.
Our findings are in contradiction to those of Furnary and
colleagues3 and Furnary and Wu,4 who recommend tight
glycemic control (<120 mg/dL) be obtained in all pa-
tients.3,4 We demonstrated in a prospective randomized
controlled study that for patients undergoing first-time iso-
lated CABG, a BG of less than 180 mg/dL is acceptable and
not inferior to the less than 120 mg/dL in perioperative out-
comes. In fact, the less than 180 mg/dL BG range was found
to be superior when obtaining and maintaining the target
range. We hypothesize that our different findings may berdiovascular Surgery c Volume 143, Number 2 323
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puterization of our intensive insulin therapy. We are able to
look beyond just the average BG values to have a better un-
derstanding of what may be themain factor affecting patient
outcomes related to BG management.Study Limitations
A possible limitation is that this was not a blinded study,
which could introduce bias into the study. However, be-
cause a computer software program was used to determine
the rate of the insulin infusion and any glucose administra-
tion, the caregiver was unable to indirectly influence a pa-
tient’s BG levels.
Another possible limitation is that we did not draw
markers of inflammation. Some studies have found that
tight glycemic control affects these inflammatory markers
and thus may affect long-term patency of the bypass grafts
and reduce ischemic events.22-24CONCLUSIONS
The findings of this study suggest that tight glucose con-
trol (90–120 mg/dL) in patients undergoing CABGmay not
be warranted in the short term. Therefore, we suggest that
all patients who undergo CABG should have a more liberal
BG target level of 120 to 180 mg/dL while hospitalized,
which is line with the current STS guidelines. Further
work is needed to determine the optimal BG level for
long-term benefit and the optimal level for patients under-
going surgery for valvular heart disease.References
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Dr Harold Lazar (Boston, Mass). I enjoyed your presentation
and appreciate you sending me the manuscript well ahead of time.
My only conflict is that I have received grant support from the Eli
Lilly Company to study the effects of glycemic control during car-
diac surgery.
Last month at the American Surgical Association, my col-
leagues and I presented a article in which we prospectively ran-
domized 82 diabetic patients undergoing CABG to receive an
aggressive glycemic group, 90 to 120, or a moderate group, 120
to 180. We found no difference in 30-day mortality, myocardial in-
farctions, neurologic complications, deep sternal wound infec-
tions, or incidence of atrial fibrillation between groups, which
was similar to your results. The patients with more aggressive con-
trol had a higher incidence of hypoglycemic events, but this did not
result in any neurologic complications. We also concluded that ag-
gressive glycemic control increases the incidence of hypoglycemic
events but does not result in any significant improvement in clini-
cal outcomes that can be achieved with more moderate control.ery c February 2012
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DAlthough I am not surprised that moderate control is safe and
effective, the question is, why does more aggressive glycemic con-
trol offer no further advantages and is potentially harmful? Your
study and our own data may provide some potential mechanisms
for answering these questions.
First, many patients undergoing CABG are already receiving
cardioprotective agents. For example, in our own study, 100%
of patients were already receiving aspirin, a statin, and a beta-
blocker, and more than 50% of patients received an angioten-
sin-converting enzyme inhibitor. Thus, the added benefits of
aggressive glucose lowering may not have as great an effect in
reducing cardiovascular events as anticipated. So my first ques-
tion is, what was the incidence of use of these agents between
the groups in your own study?
Second, in our study, moderate glycemic control achieved an
average serum glucose of 135 versus 103 for the aggressive group.
Thus, evenwhen aiming for more moderate control, tight glycemic
control was still achieved. We found that using our paper algo-
rithm, both the moderate and aggressive groups remained in their
respective target ranges 100% of the time. Do you think that the
computerized Glucommander system could have accounted for
the wider variation in your patients receiving the more aggressive
control? Less than 50% of patients in your study were diabetic.
Could the larger incidence of nondiabetic patients have made
tighter glycemic control more vulnerable to these hypoglycemic
episodes?
Third, we have shown in our series that one of the benefits of
glycemic control is that markers of inflammation, such as free fatty
acids, are significantly reduced. In our recent study, aggressive
control actually resulted in a significant decrease in free fatty acids
compared with the more moderate control. This ultimately may re-
sult in long-term benefits, such as improved graft patency and re-
duced ischemic events. Did you measure any inflammatory
markers and do you have any long-term follow-up for these pa-
tients as to the incidence of recurrent ischemic episodes and the
need for re-revascularization? It may turn out that more aggressive
control might still have some hidden long-term benefits.The Journal of Thoracic and CaFinally, as we have seen in our earlier studies, moderate glyce-
mic control alone has resulted in a significant decrease in morbid-
ity and mortality, which may be difficult to improve on with more
aggressive control.
In summary, although I agree that the optimal range for gly-
cemic control in cardiac surgery patients is 120 to 180, we
should all remember that although the exact value for achieving
optimal perioperative glycemic control is still unknown and the
subject of numerous studies and intense debate, the concept of
perioperative glycemic control using continuous insulin infu-
sions in our patients is well established and its importance is
not debatable.
Dr Desai. In terms of whether we had data regarding cardiac
medications that the patients were taking, we did collect medica-
tion data for all the patients who were enrolled in the study, but
this was not analyzed. In regard to inflammatory markers, we
did measure erythrocyte sedimentation rate and C-reactive protein
levels in all patients who were enrolled in this study. I do not have
the data here on the levels in the strict group versus the liberal
group.
In terms of the computer algorithm versus the paper algorithm
and the wide variation, I think having our study open to a lot of
nondiabetic patients did contribute to the wide variability. These
are patients who are not normally hyperglycemic, but because
of the stress of surgery and the other factors involved, their glu-
cose levels were severely elevated to the point that they are started
on insulin infusions. We also noticed that once we got to approx-
imately 48 hours after the surgery, the patients were starting to
take an oral diet. Because of this, we also noticed large spikes
in their glucose, which the computer algorithm does not currently
into account. Deviations from target range was common because
of this phenomenon and have been seen in other similar studies.
It is excellent, Dr Lazar, that your study was able to maintain pa-
tients 100% in their target range. We believe further work needs to
be done with the Glucommander computerized system in regard to
adjusting the algorithm once the patients start taking an oral diet
after their surgery to maintain their target range.rdiovascular Surgery c Volume 143, Number 2 325
